CVRX Stock Analysis: CVRx | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 81m USD | 12M Return: -60.3% | US1266381052 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 3.15M
Qual. Beats: 0
Rev. Trend: 97.2%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality
CVRx, Inc. is a Minneapolis-based medical device company focused on neuromodulation therapies for cardiovascular disease. The company manufactures and markets Barostim, an implantable technology designed to trigger the bodys natural baroreflex to manage heart failure symptoms. This approach utilizes electrical pulses to the carotid artery to modulate the autonomic nervous system, distinguishing it from traditional cardiac rhythm management devices that focus on direct heart muscle stimulation.
The company operates within the Health Care Equipment sector, where high barriers to entry often include rigorous clinical trial requirements and complex regulatory approval processes. CVRx utilizes a multi-channel distribution strategy involving a direct sales force and independent distributors to reach markets in the United States and Europe. Investors may find it useful to examine ValueRay for further data on the companys market positioning. As a commercial-stage entity, the business model relies on increasing clinical adoption and securing stable reimbursement pathways from healthcare payers.
- Barostim adoption rates and implant volume drive primary revenue growth
- CMS reimbursement policy changes impact hospital adoption and procedure margins
- Clinical trial data expansion influences physician referral patterns and market penetration
- Operating cash burn and pathway to profitability dictate future capital requirements
- Strategic expansion of direct sales force increases US commercial market share
| Net Income: -52.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.43 > 0.02 and ΔFCF/TA -8.44 > 1.0 |
| NWC/Revenue: 128.1% < 20% (prev 194.8%; Δ -66.72% < -1%) |
| CFO/TA -0.44 > 3% & CFO -40.5m > Net Income -52.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 8.04 > 1.5 & < 3 |
| Outstanding Shares: last quarter (26.5m) vs 12m ago 1.70% < -2% |
| Gross Margin: 86.60% > 18% (prev 83.69%; Δ 2.91% > 0.5%) |
| Asset Turnover: 57.77% > 50% (prev 45.71%; Δ 12.06% > 0%) |
| Interest Coverage Ratio: -7.62 > 6 (EBIT TTM -45.9m / Interest Expense TTM 6.03m) |
| A: 0.85 (Total Current Assets 89.5m - Total Current Liabilities 11.1m) / Total Assets 92.3m |
| B: -6.69 (Retained Earnings -617.8m / Total Assets 92.3m) |
| C: -0.43 (EBIT TTM -45.9m / Avg Total Assets 105.9m) |
| D: 0.28 (Book Value of Equity 20.0m / Total Liabilities 72.3m) |
| Altman-Z'' = -18.88 = D |
| DSRI: 1.17 (Receivables 9.40m/7.15m, Revenue 61.2m/54.7m) |
| GMI: 0.97 (GM 83.69% / 86.60%) |
| AQI: 1.30 (AQ_t 0.00 / AQ_t-1 0.00) |
| SGI: 1.12 (Revenue 61.2m / 54.7m) |
| TATA: -0.12 (NI -52.0m - CFO -40.5m) / TA 92.3m) |
| Beneish M = -2.67 (Cap -4..+1) = A |
As of September 03, 2026, the stock is trading at USD 3.07 with a total of 529,959 shares traded. Over the past week, the price has changed by -6.12%, over one month by -44.18%, over three months by -43.46% and over the past year by -60.28%.
Current recommended Stop Loss: 2.70 (which is 12.1% or 1.1 ATR below the current price).
CVRx has received a consensus analysts rating of 4.57. Therefore, it is recommended to buy CVRX.
- StrongBuy: 5
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 4.6 | 49.2% |
P/S = 1.3236
P/B = 3.9522
Revenue TTM = 61.2m USD
EBIT TTM = -45.9m USD
EBITDA TTM = -45.0m USD
Long Term Debt = 58.6m USD (from longTermDebt, last quarter)
Short Term Debt = 371k USD (from shortTermDebt, last quarter)
Debt = 60.2m USD (from shortLongTermDebtTotal, last quarter) + Leases 819k
Net Debt = -4.38m USD (calculated: Debt 60.2m - CCE 64.6m)
Enterprise Value = 76.6m USD (81.0m + Debt 60.2m - CCE 64.6m)
Interest Coverage Ratio = -7.62 (Ebit TTM -45.9m / Interest Expense TTM 6.03m)
EV/FCF = -1.94x (Enterprise Value 76.6m / FCF TTM -39.5m)
FCF Yield = -51.57% (FCF TTM -39.5m / Enterprise Value 76.6m)
FCF Margin = -64.57% (FCF TTM -39.5m / Revenue TTM 61.2m)
Net Margin = -84.93% (Net Income TTM -52.0m / Revenue TTM 61.2m)
Gross Margin = 86.60% ((Revenue TTM 61.2m - Cost of Revenue TTM 8.20m) / Revenue TTM)
Gross Margin QoQ = 87.39% (prev 87.22%)
Tobins Q-Ratio = 0.83 (Enterprise Value 76.6m / Total Assets 92.3m)
Interest Expense / Debt = 10.01% (Interest Expense 6.03m / Debt 60.2m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -36.3m (EBIT -45.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.97 (Total Current Assets 89.5m / Total Current Liabilities 15.0m)
Debt / Equity = 3.02 (Debt 60.2m / totalStockholderEquity, last quarter 20.0m)
Debt / EBITDA = 0.10 (negative EBITDA) (Net Debt -4.38m / EBITDA -45.0m)
Debt / FCF = 0.11 (negative FCF - burning cash) (Net Debt -4.38m / FCF TTM -39.5m)
Total Stockholder Equity = 34.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -49.06% (Net Income -52.0m / Total Assets 92.3m)
RoE = -152.4% (Net Income TTM -52.0m / Total Stockholder Equity 34.1m)
RoCE = -49.58% (EBIT -45.9m / Capital Employed (Equity 34.1m + L.T.Debt 58.6m))
RoIC = -46.26% (negative operating profit) (NOPAT -36.3m / Invested Capital 78.5m)
WACC = 10.16% (E(81.0m)/V(141.2m) * Re(11.83%) + D(60.2m)/V(141.2m) * Rd(10.01%) * (1-Tc(0.21)))
Discount Rate = 11.83% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.19 | Cagr: 10.38%
[DCF] Fair Price = unknown (Cash Flow -39.5m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.20 | # QB: 0
Revenue Correlation: 97.25 | Revenue CAGR: 20.73% | SUE: 0.89 | # QB: 1
EPS current Quarter (2026-09-30): EPS=-0.50 | Chg30d=-3.84% | Revisions=+12% | Analysts=5
EPS current Year (2026-12-31): EPS=-2.02 | Chg30d=-2.76% | Revisions=+0% | GrowthEPS=+1.1% | GrowthRev=+3.9%
EPS next Year (2027-12-31): EPS=-1.88 | Chg30d=+0.90% | Revisions=+12% | GrowthEPS=+6.9% | GrowthRev=+12.4%
[Analyst] Revisions Ratio: +12% (up=8, down=6)